CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Marker-Agnostic Tumor Anchoring Chimeras Enable pH-Gated Immune Engagement.
Marker-Agnostic Tumor Anchoring Chimeras Enable pH-Gated Immune Engagement.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
靶向癌症免疫疗法通常依赖细胞表面抗原来引导免疫反应。然而,许多肿瘤缺乏肿瘤特异性标志物,或会下调其表达,从而限制了抗原导向策略的适用性。相比之下,肿瘤酸化是实体癌近乎普遍的特征,源于代谢失调导致肿瘤微环境(TME)细胞外酸化。
我们利用这一特征开发了非标志物依赖的肿瘤锚定嵌合体(MATRAC):一种pH敏感融合蛋白,可在不依赖抗原的情况下介导癌细胞与免疫效应细胞形成三元复合物。MATRAC利用白喉毒素转位结构域(tdDT)的pH依赖性构象转换驱动膜插入,使tdDT及其Fc融合形式(tdDT-Fc)能够在类似TME的酸性环境中选择性锚定于细胞,而在生理pH下保持不活跃。为证明其pH依赖性免疫激活能力,我们设计了一种荧光素标记的tdDT-Fc变体,使其在酸性条件下锚定于肿瘤细胞,并呈递合成表位以募集抗荧光素CAR-T 细胞。这些发现确立了基于tdDT的MATRAC作为模块化、可响应TME的平台,可实现不依赖特定抗原的免疫接合,并支持其作为下一代pH靶向免疫疗法的潜力。
Targeted cancer immunotherapies typically depend on cell surface antigens to direct immune responses.
However, many tumors either lack tumor-specific markers or downregulate their expression, limiting the applicability of antigen-directed strategies. In contrast, tumor acidosis represents a nearly universal hallmark of solid cancers, arising from dysregulated metabolism that acidifies the extracellular tumor microenvironment (TME).
Here, we leverage this feature to develop Marker-Agnostic Tumor Anchoring Chimeras (MATRACs), pH-sensitive fusion proteins that mediate ternary complex formation between cancer cells and immune effector cells in an antigen-independent manner.
MATRACs harness the diphtheria toxin translocation domain (tdDT), whose pH-dependent conformational switch drives membrane insertion, allowing tdDT and its Fc-fused form (tdDT-Fc) to anchor selectively to cells in TME-like acidity while remaining inactive at physiological pH. To demonstrate pH-dependent immune activation, we designed a fluorescein-tagged tdDT-Fc variant that anchors to tumor cells in acidic conditions and presents a synthetic epitope enabling recruitment of antifluorescein CAR T cells.
These findings establish tdDT-based MATRACs as a modular, TME-responsive platform for antigen-agnostic immune engagement and support their potential for next-generation pH-targeted immunotherapies.
MEMBER ACCOUNT
登录成功会直接打开下一页。